Archief

89ZR-CX-072-PET scan studie

5 mei 2021

ACT

12 april 2021

Optimal Timing of a tailored Physical Activity program during chemotherapeutic Cancer Treatment to reduce Long-term Cardiovascular Morbidity METc nr: 2012/260 Onderzoekscode: ON76 ClinicalTrials.gov registratie: NCT01642680 Samenvatting Het aantal…

ACT

6 mei 2021

Optimal Timing of a tailored Physical Activity program during chemotherapeutic Cancer Treatment to reduce Long-term Cardiovascular Morbidity METc nr: 2012/260 Onderzoekscode: ON76 ClinicalTrials.gov registratie: NCT01642680 Samenvatting Het aantal…

AIPAC

12 april 2021

Active Immunotherapy PAClitaxel: A multicentre, Phase IIb, randomized, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-31g fusion protein) or placebo as adjunctive…

ALT-GIST EORTC 1321

ALT-GIST: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST). EORTC study…

AMG 479

A phase 3, multicenter, randomized, double-blind, placebo controlled, trial of AMG 479 or placebo in combination with Gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas.

BLU-667

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors. Protocolnummer: BLU-667-1101 Eudract…

BLU-667 studie (named-patient programma)

Zie BEACON: NET – medullair schildkliercarcinoom – palliatief – BLU-667 studie (named-patient programma)

Breast Optical Imaging

Validation of Uptake of a VEGF-targeted Optical Fluorescent Imaging Tracer in Surgical Specimens of Breast Cancer and Application of Pre- and Intra-operative Human Molecular Fluorescence Imaging Techniques. A…

CA209-143

Phase IIb Study of Nivolumab in comb. with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM) Protocolnummer: CA209143 Eudractnummer: 2013-003738-34 METc nummer: 2014525 Onderzoekscode: O118 ECG…

CA209-238

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at…

CA209-577

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer. (CheckMate 577: CHECKpoint pathway and nivoluMab…

CA209-714

CA209-714: A double-blind, randomized, two arm phase 2 study of nivolumab in combination with ipilimumab versus nivolumab in combination with ipilimumab placebo squamous cell carcinoma of the head…

CA209-76K

A phase 3, randomized, double-blind study of adjuvant immunotherapy with Nivolumab versus placebo after complete resection of stage IIB/C melanoma (CA209-76K) Protocolnummer: CA20976K EudraCT nummer: 2019-001230-34 METc nummer:…